(Cohort 2024)
Development of an integrated platform for studying and on-demand generation of oligonucleotide therapeutics
Health & Wellness
Samir Hamdan
Vlad-Stefan Raducanu's research focuses on the intricate interactions between nucleic acids and associated proteins, explored through a multidisciplinary approach combining biophysical, biochemical, and computational methods. Holding a BS in Biophysics from the University of Bucharest and both an MS and PhD in Biochemistry, Biophysics, and Molecural Biology from KAUST, Vlad brings extensive expertise to the field. Prior to joining the Fellowship, Vlad served as an Associate Principal Scientist at AstraZeneca. His current research aims to revolutionize the design of antisense oligonucleotide (ASO) therapeutics by developing predictive in vitro assays that integrate enzymatic, structural, single-melecule, and computational data. This work holds high translational potential including streamlining ASO drug development, reduce production time and cost while enhancing therapeutic outcomes for patients.